3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
NIH
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Lung Neoplasms
28
Ovarian Neoplasms
27
Fallopian Tube Neoplasms
24
Carcinoma, Non-Small-Cell Lung
21
Colorectal Neoplasms
17
Pancreatic Neoplasms
11
Glioblastoma
11
Melanoma
10
Carcinoma, Renal Cell
10
Carcinoma, Hepatocellular
10
Breast Neoplasms
9
Squamous Cell Carcinoma of Head and Neck
8
Lymphoma, Large B-Cell, Diffuse
8
Urinary Bladder Neoplasms
7
Neoplasm Metastasis
7
Colonic Neoplasms
7
Brenner Tumor
7
Uterine Cervical Neoplasms
6
Rectal Neoplasms
6
Prostatic Neoplasms
6
Mycosis Fungoides
6
Leukemia, Lymphocytic, Chronic, B-Cell
6
Brain Neoplasms
6
Triple Negative Breast Neoplasms
5
Multiple Myeloma
5
Lymphoma, T-Cell, Cutaneous
5
Sezary Syndrome
4
Sarcoma
4
Neoplasms
4
Nasopharyngeal Carcinoma
4
Interventions
Imatinib Mesylate
67
Sunitinib
27
nilotinib
14
regorafenib
13
ripretinib
10
avapritinib
5
Ipilimumab
5
Dasatinib
5
spartalizumab
4
Laparoscopy
4
CTLA-4 Antigen
4
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
4
pexidartinib
3
pazopanib
3
binimetinib
3
Temozolomide
3
Paclitaxel
3
Oxaliplatin
3
Nivolumab
3
Midazolam
3
Leucovorin
3
Gemcitabine
3
Bevacizumab
3
trametinib
2
tanespimycin
2
ponatinib
2
pembrolizumab
2
masitinib
2
famitinib
2
envafolimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Gastrointestinal Stromal Tumors
×
Disulfides
×
Clear all
NCT00324987
2017-09-14
S0502
National Cancer Institute (NCI)
Phase 3
Terminated
12 enrolled
13 charts